(June 30, 2021, 11:26 AM EDT) -- ALEXANDRIA, Va. — In a June 28 filing with the Patent Trial and Appeal Board, Fresenius Kabi USA LLC maintains that a patented method of achieving a measurement of efficacy for a rheumatoid arthritis (RA) treatment should be canceled as obvious and anticipated....